액체생검 시장 규모, 점유율, 동향 분석 보고서 : 바이오마커별, 기술별, 검체 유형별, 용도별, 임상 응용별, 최종 용도별, 제품별, 지역별, 부문별 예측(2026-2033년)

Liquid Biopsy Market Size, Share & Trends Analysis Report By Biomarker, By Technology, By Sample Type, By Application, By Clinical Application, By End Use, By Product, By Region, And Segment Forecasts, 2026 - 2033

US $ 5,950 ￦ 8,951,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,455,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,464,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

액체생검 시장 요약

세계의 액체생검 시장 규모는 2025년에 136억 달러로 추정되며, 2033년까지 325억 7,000만 달러에 달할 것으로 예측됩니다.

2026-2033년 연평균 복합 성장률(CAGR) 11.52%를 나타낼 것으로 예측됩니다. 암 발병률 증가, 암 진단 기술의 발전, 저침습적 암 진단법에 대한 수요 증가 등의 요인으로 업계는 지속적으로 성장하고 있습니다.

또한 다중 암 조기 발견 검사의 보급과 개발의 진전에 힘입어 액체생검 분석 및 검사법 개발을 위한 지속적인 연구가 진행되면서 전체 시장의 성장 기회를 제공합니다. 액체생검은 종양과 관련된 유전자 변이를 검출하기 위한 첨단 검사 기술입니다. 또한 종양의 층화 및 정밀한 암 치료에도 활용되고 있습니다. 예를 들어 2023년 1월, 가드앤트헬스(Guardant Health)는 ESR1 변이형 유방암 진단을 위한 동반진단제로서 액체생검법 '가드앤트 360 CDx'의 FDA 승인을 획득했습니다. 액체생검의 사용을 촉진하는 이러한 업계의 최근 혁신, 발전 및 확장은 시장을 주도하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 개요

제3장 시장 변수, 동향, 범위

제4장 검체 유형별 사업 분석

제5장 바이오마커별 사업 분석

제6장 기술별 사업 분석

제7장 용도별 사업 분석

제8장 최종 용도별 사업 분석

제9장 임상 응용별 사업 분석

제10장 제품별 사업 분석

제11장 지역별 사업 분석

제12장 경쟁 구도

KSA

영문 목차

영문목차

Liquid Biopsy Market Summary

The global liquid biopsy market size was estimated at USD 13.60 billion in 2025 and is projected to reach USD 32.57 billion by 2033, growing at a CAGR of 11.52% from 2026 to 2033. The industry is witnessing growth due to factors such as the growing prevalence of cancer, technological advancements in cancer diagnostics, and rising preference for minimally invasive cancer diagnostics.

Moreover, ongoing research for the development of liquid biopsy assays and tests, aided by the rising adoption and development of multi-cancer early detection tests, is providing a major opportunity for the growth of the overall market. Liquid biopsy is an advanced testing technology for the detection of genetic alterations related tumor. It has also been utilized to stratify tumors and deliver precise cancer treatment. For instance, in January 2023, Guardant Health received FDA approval for Guardant360 CDx, its liquid biopsy assay as companion diagnostics for ESR1 mutant breast cancer diagnosis. These recent innovations, advancements, and expansions in the industry promoting the use of liquid biopsy are driving the market.

Global Liquid Biopsy Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global liquid biopsy market report based on sample type, biomarker, technology, application, end use, clinical application, product, and region:

• Sample Type Outlook (Revenue, USD Billion, 2021 - 2033)
• Blood Sample
• Others
• Biomarker Outlook (Revenue, USD Billion, 2021 - 2033)
• Circulating Tumor Cells (CTCs)
• Circulating Nucleic Acids
• Exosomes/Microvesicles
• Others
• Technology Outlook (Revenue, USD Billion, 2021 - 2033)
• Multi-gene parallel Analysis (NGS)
• Single Gene Analysis (PCR Microarrays)
• Application Outlook (Revenue, USD Billion, 2021 - 2033)
• Cancer
  • Lung Cancer
  • Prostate Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Leukemia
  • Gastrointestinal Cancer
  • Others
• Reproductive Health
  • Others
• End Use Outlook (Revenue, USD Billion, 2021 - 2033)
• Hospitals and Laboratories
• Specialty Clinics
• Academic and Research Centers
• Others
• Clinical Application Outlook (Revenue, USD Billion, 2021 - 2033)
• Therapy Selection
• Treatment Monitoring
• Early Cancer Screening
• Recurrence Monitoring
• Others
• Product Outlook (Revenue, USD Billion, 2021 - 2033)
• Instruments
• Consumables Kits and Reagents
• Software and Services
• Regional Outlook (Revenue, USD Billion, 2021- 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation
  • 1.1.1. Market Definitions
• 1.2. Objectives
  • 1.2.1. OBJECTIVE - 1
  • 1.2.2. OBJECTIVE - 2
  • 1.2.3. OBJECTIVE - 3
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. PURCHASED DATABASE
  • 1.4.2. GVR'S INTERNAL DATABASE
  • 1.4.3. SECONDARY SOURCES
  • 1.4.4. PRIMARY RESEARCH
• 1.5. Information or Data Analysis
  • 1.5.1. DATA ANALYSIS MODELS
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. COMMODITY FLOW ANALYSIS
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. List of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers
  • 3.4.1. Increasing prevalence of cancer
  • 3.4.2. Growing geriatric population
  • 3.4.3. Technological advancements
  • 3.4.4. Increasing preference for noninvasive treatment
• 3.5. Market Restraint Analysis
  • 3.5.1. Patent expiry of blockbuster drugs prescribed
• 3.6. Business Environment Analysis
  • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
  • 3.6.2. Porter's Five Forces Analysis

Chapter 4. Sample Type Business Analysis

• 4.1. Liquid Biopsy Market: Type Movement Analysis
• 4.2. Blood Sample
  • 4.2.1. Blood Sample Market, 2021 - 2033 (USD Million)
• 4.3. Others
  • 4.3.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Biomarker Business Analysis

• 5.1. Liquid Biopsy Market: Biomarker Movement Analysis
• 5.2. Circulating Tumor Cells (CTCs)
  • 5.2.1. Circulating Tumor Cells (CTCs) Market, 2021 - 2033 (USD Million)
• 5.3. Circulating Nucleic Acids
  • 5.3.1. Circulating Nucleic Acids Market, 2021 - 2033 (USD Million)
• 5.4. Exosomes/Microvesicles
  • 5.4.1. Exosomes/Microvesicles Market, 2021 - 2033 (USD Million)
• 5.5. Others
  • 5.5.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Technology Business Analysis

• 6.1. Liquid Biopsy Market: Technology Movement Analysis
• 6.2. Multi-gene-parallel Analysis (NGS)
  • 6.2.1. Multi-gene-parallel Analysis (NGS) Market, 2021 - 2033 (USD Million)
• 6.3. Single Gene Analysis (PCR Microarrays)
  • 6.3.1. Single Gene Analysis (PCR Microarrays) Market, 2021 - 2033 (USD Million)

Chapter 7. Application Business Analysis

• 7.1. Liquid Biopsy Market: Application Movement Analysis
• 7.2. Cancer
  • 7.2.1. Cancer Market, 2021 - 2033 (USD Million)
    • 7.2.1.1. Lung Cancer
      • 7.2.1.1.1. Lung Cancer Market, 2021 - 2033 (USD Million)
    • 7.2.1.2. Prostate Cancer
      • 7.2.1.2.1. Prostate Cancer Market, 2021 - 2033 (USD Million)
    • 7.2.1.3. Breast Cancer
      • 7.2.1.3.1. Breast Cancer Market, 2021 - 2033 (USD Million)
    • 7.2.1.4. Colorectal Cancer
      • 7.2.1.4.1. Colorectal Cancer Market, 2021 - 2033 (USD Million)
    • 7.2.1.5. Leukemia
      • 7.2.1.5.1. Leukemia Market, 2021 - 2033 (USD Million)
    • 7.2.1.6. Gastrointestinal Cancer
      • 7.2.1.6.1. Gastrointestinal Cancer Market, 2021 - 2033 (USD Million)
    • 7.2.1.7. Others
      • 7.2.1.7.1. Others Market, 2021 - 2033 (USD Million)
• 7.3. Reproductive Health
  • 7.3.1. Reproductive Health Market, 2021 - 2033 (USD Million)
• 7.4. Others
  • 7.4.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. End Use Business Analysis

• 8.1. Liquid Biopsy Market: End-Use Movement Analysis
• 8.2. Hospitals and Laboratories
  • 8.2.1. Hospitals and Laboratories Market, 2021 - 2033 (USD Million)
• 8.3. Specialty Clinics
  • 8.3.1. Specialty Clinics Market, 2021 - 2033 (USD Million)
• 8.4. Academic and Research Centers
  • 8.4.1. Academic and Research Centers Market, 2021 - 2033 (USD Million)
• 8.5. Others
  • 8.5.1. Others Liquid Biopsy Market, 2021 - 2033 (USD Million)

Chapter 9. Clinical Application Business Analysis

• 9.1. Liquid Biopsy Market: Clinical Application Movement Analysis
• 9.2. Therapy Selection
  • 9.2.1. Therapy Selection Market, 2021 - 2033 (USD Million)
• 9.3. Treatment Monitoring
  • 9.3.1. Treatment Monitoring Market, 2021 - 2033 (USD Million)
• 9.4. Early Cancer Screening
  • 9.4.1. Early Cancer Screening Market, 2021 - 2033 (USD Million)
• 9.5. Recurrence Monitoring
  • 9.5.1. Recurrence Monitoring Market, 2021 - 2033 (USD Million)
• 9.6. Others
  • 9.6.1. Others Liquid Biopsy Market, 2021 - 2033 (USD Million)

Chapter 10. Product Business Analysis

• 10.1. Liquid Biopsy Market: Product Movement Analysis
• 10.2. Instruments
  • 10.2.1. Instruments Market, 2021 - 2033 (USD Million)
• 10.3. Consumables Kits and Reagents
  • 10.3.1. Consumables Kits and Reagents Market, 2021 - 2033 (USD Million)
• 10.4. Software and Services
  • 10.4.1. Software and Services Market, 2021 - 2033 (USD Million)

Chapter 11. Regional Business Analysis

• 11.1. Liquid Biopsy Market Share By Region, 2025 & 2033
• 11.2. North America
  • 11.2.1. North America Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.2.2. U.S.
    • 11.2.2.1. Key Country Dynamics
    • 11.2.2.2. Target Disease Prevalence
    • 11.2.2.3. Competitive Scenario
    • 11.2.2.4. Regulatory Framework
    • 11.2.2.5. Reimbursement Scenario
    • 11.2.2.6. U.S. Liquid biopsy market, 2021 - 2033 (USD MILLION)
  • 11.2.3. Canada
    • 11.2.3.1. Key Country Dynamics
    • 11.2.3.2. Target Disease Prevalence
    • 11.2.3.3. Competitive Scenario
    • 11.2.3.4. Regulatory Framework
    • 11.2.3.5. Reimbursement Scenario
    • 11.2.3.6. Canada Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.2.4. Mexico
    • 11.2.4.1. Key Country Dynamics
    • 11.2.4.2. Target Disease Prevalence
    • 11.2.4.3. Competitive Scenario
    • 11.2.4.4. Regulatory Framework
    • 11.2.4.5. Reimbursement Scenario
    • 11.2.4.6. Mexico Liquid biopsy market, 2021 - 2033 (USD Million)
• 11.3. Europe
  • 11.3.1. Europe Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.3.2. Germany
    • 11.3.2.1. Key Country Dynamics
    • 11.3.2.2. Target Disease Prevalence
    • 11.3.2.3. Competitive Scenario
    • 11.3.2.4. Regulatory Framework
    • 11.3.2.5. Reimbursement Scenario
    • 11.3.2.6. Germany Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.3.3. UK
    • 11.3.3.1. Key Country Dynamics
    • 11.3.3.2. Target Disease Prevalence
    • 11.3.3.3. Competitive Scenario
    • 11.3.3.4. Regulatory Framework
    • 11.3.3.5. Reimbursement Scenario
    • 11.3.3.6. UK Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.3.4. France
    • 11.3.4.1. Key Country Dynamics
    • 11.3.4.2. Target Disease Prevalence
    • 11.3.4.3. Competitive Scenario
    • 11.3.4.4. Regulatory Framework
    • 11.3.4.5. Reimbursement Scenario
    • 11.3.4.6. France Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.3.5. Italy
    • 11.3.5.1. Key Country Dynamics
    • 11.3.5.2. Target Disease Prevalence
    • 11.3.5.3. Competitive Scenario
    • 11.3.5.4. Regulatory Framework
    • 11.3.5.5. Reimbursement Scenario
    • 11.3.5.6. Italy Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.3.6. Spain
    • 11.3.6.1. Key Country Dynamics
    • 11.3.6.2. Target Disease Prevalence
    • 11.3.6.3. Competitive Scenario
    • 11.3.6.4. Regulatory Framework
    • 11.3.6.5. Reimbursement Scenario
    • 11.3.6.6. Spain Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.3.7. Denmark
    • 11.3.7.1. Key Country Dynamics
    • 11.3.7.2. Target Disease Prevalence
    • 11.3.7.3. Competitive Scenario
    • 11.3.7.4. Regulatory Framework
    • 11.3.7.5. Reimbursement Scenario
    • 11.3.7.6. Denmark Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.3.8. Sweden
    • 11.3.8.1. Key Country Dynamics
    • 11.3.8.2. Target Disease Prevalence
    • 11.3.8.3. Competitive Scenario
    • 11.3.8.4. Regulatory Framework
    • 11.3.8.5. Reimbursement Scenario
    • 11.3.8.6. Sweden Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.3.9. Norway
    • 11.3.9.1. Key Country Dynamics
    • 11.3.9.2. Target Disease Prevalence
    • 11.3.9.3. Competitive Scenario
    • 11.3.9.4. Regulatory Framework
    • 11.3.9.5. Reimbursement Scenario
    • 11.3.9.6. Norway Liquid biopsy market, 2021 - 2033 (USD Million)
• 11.4. Asia Pacific
  • 11.4.1. Asia Pacific Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.4.2. Japan
    • 11.4.2.1. Key Country Dynamics
    • 11.4.2.2. Target Disease Prevalence
    • 11.4.2.3. Competitive Scenario
    • 11.4.2.4. Regulatory Framework
    • 11.4.2.5. Reimbursement Scenario
    • 11.4.2.6. Japan Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.4.3. China
    • 11.4.3.1. Key Country Dynamics
    • 11.4.3.2. Target Disease Prevalence
    • 11.4.3.3. Competitive Scenario
    • 11.4.3.4. Regulatory Framework
    • 11.4.3.5. Reimbursement Scenario
    • 11.4.3.6. China Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.4.4. India
    • 11.4.4.1. Key Country Dynamics
    • 11.4.4.2. Target Disease Prevalence
    • 11.4.4.3. Competitive Scenario
    • 11.4.4.4. Regulatory Framework
    • 11.4.4.5. Reimbursement Scenario
    • 11.4.4.6. India Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.4.5. South Korea
    • 11.4.5.1. Key Country Dynamics
    • 11.4.5.2. Target Disease Prevalence
    • 11.4.5.3. Competitive Scenario
    • 11.4.5.4. Regulatory Framework
    • 11.4.5.5. Reimbursement Scenario
    • 11.4.5.6. South Korea Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.4.6. Australia
    • 11.4.6.1. Key Country Dynamics
    • 11.4.6.2. Target Disease Prevalence
    • 11.4.6.3. Competitive Scenario
    • 11.4.6.4. Regulatory Framework
    • 11.4.6.5. Reimbursement Scenario
    • 11.4.6.6. Australia Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.4.7. Thailand
    • 11.4.7.1. Key Country Dynamics
    • 11.4.7.2. Target Disease Prevalence
    • 11.4.7.3. Competitive Scenario
    • 11.4.7.4. Regulatory Framework
    • 11.4.7.5. Reimbursement Scenario
    • 11.4.7.6. Thailand Liquid biopsy market, 2021 - 2033 (USD Million)
• 11.5. Latin America
  • 11.5.1. Latin America Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.5.2. Brazil
    • 11.5.2.1. Key Country Dynamics
    • 11.5.2.2. Target Disease Prevalence
    • 11.5.2.3. Competitive Scenario
    • 11.5.2.4. Regulatory Framework
    • 11.5.2.5. Reimbursement Scenario
    • 11.5.2.6. Brazil Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.5.3. Argentina
    • 11.5.3.1. Key Country Dynamics
    • 11.5.3.2. Target Disease Prevalence
    • 11.5.3.3. Competitive Scenario
    • 11.5.3.4. Regulatory Framework
    • 11.5.3.5. Reimbursement Scenario
    • 11.5.3.6. Argentina Liquid biopsy market, 2021 - 2033 (USD Million)
• 11.6. Middle East and Africa
  • 11.6.1. Middle East and Africa Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.6.2. South Africa
    • 11.6.2.1. Key Country Dynamics
    • 11.6.2.2. Target Disease Prevalence
    • 11.6.2.3. Competitive Scenario
    • 11.6.2.4. Regulatory Framework
    • 11.6.2.5. Reimbursement Scenario
    • 11.6.2.6. South Africa Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.6.3. Saudi Arabia
    • 11.6.3.1. Key Country Dynamics
    • 11.6.3.2. Target Disease Prevalence
    • 11.6.3.3. Competitive Scenario
    • 11.6.3.4. Regulatory Framework
    • 11.6.3.5. Reimbursement Scenario
    • 11.6.3.6. Saudi Arabia Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.6.4. UAE
    • 11.6.4.1. Key Country Dynamics
    • 11.6.4.2. Target Disease Prevalence
    • 11.6.4.3. Competitive Scenario
    • 11.6.4.4. Regulatory Framework
    • 11.6.4.5. Reimbursement Scenario
    • 11.6.4.6. UAE Liquid biopsy market, 2021 - 2033 (USD Million)
  • 11.6.5. Kuwait
    • 11.6.5.1. Key Country Dynamics
    • 11.6.5.2. Target Disease Prevalence
    • 11.6.5.3. Competitive Scenario
    • 11.6.5.4. Regulatory Framework
    • 11.6.5.5. Reimbursement Scenario
    • 11.6.5.6. Kuwait Liquid biopsy market, 2021 - 2033 (USD Million)

Chapter 12. Competitive Landscape

• 12.1. Participant's overview
• 12.2. Financial performance
• 12.3. Participant categorization
  • 12.3.1. Market Leaders
  • 12.3.2. Liquid Biopsy Market Share Analysis, 2025
  • 12.3.3. Company Profiles
    • 12.3.3.1. ANGLE plc
      • 12.3.3.1.1. Company Overview
      • 12.3.3.1.2. Financial Performance
      • 12.3.3.1.3. Product Benchmarking
      • 12.3.3.1.4. Strategic Initiatives
    • 12.3.3.2. Oncimmune Holdings PLC
      • 12.3.3.2.1. Company Overview
      • 12.3.3.2.2. Financial Performance
      • 12.3.3.2.3. Product Benchmarking
      • 12.3.3.2.4. Strategic Initiatives
    • 12.3.3.3. Guardant Health
      • 12.3.3.3.1. Company Overview
      • 12.3.3.3.2. Financial Performance
      • 12.3.3.3.3. Product Benchmarking
      • 12.3.3.3.4. Strategic Initiatives
    • 12.3.3.4. Myriad Genetics, Inc.
      • 12.3.3.4.1. Company Overview
      • 12.3.3.4.2. Financial Performance
      • 12.3.3.4.3. Product Benchmarking
      • 12.3.3.4.4. Strategic Initiatives
    • 12.3.3.5. Biocept, Inc.
      • 12.3.3.5.1. Company Overview
      • 12.3.3.5.2. Financial Performance
      • 12.3.3.5.3. Product Benchmarking
      • 12.3.3.5.4. Strategic Initiatives
    • 12.3.3.6. Lucence Health Inc.
      • 12.3.3.6.1. Company Overview
      • 12.3.3.6.2. Financial Performance
      • 12.3.3.6.3. Product Benchmarking
      • 12.3.3.6.4. Strategic Initiatives
    • 12.3.3.7. Freenome Holdings, Inc.
      • 12.3.3.7.1. Company Overview
      • 12.3.3.7.2. Financial Performance
      • 12.3.3.7.3. Product Benchmarking
      • 12.3.3.7.4. Strategic Initiatives
    • 12.3.3.8. F. Hoffmann-La Roche Ltd.
      • 12.3.3.8.1. Company Overview
      • 12.3.3.8.2. Financial Performance
      • 12.3.3.8.3. Product Benchmarking
      • 12.3.3.8.4. Strategic Initiatives
    • 12.3.3.9. QIAGEN
      • 12.3.3.9.1. Company Overview
      • 12.3.3.9.2. Financial Performance
      • 12.3.3.9.3. Product Benchmarking
      • 12.3.3.9.4. Strategic Initiatives
    • 12.3.3.10. Illumina, Inc.
      • 12.3.3.10.1. Company Overview
      • 12.3.3.10.2. Financial Performance
      • 12.3.3.10.3. Product Benchmarking
      • 12.3.3.10.4. Strategic Initiatives
    • 12.3.3.11. Thermo Fisher Scientific, Inc.
      • 12.3.3.11.1. Company Overview
      • 12.3.3.11.2. Financial Performance
      • 12.3.3.11.3. Product Benchmarking
      • 12.3.3.11.4. Strategic Initiatives
    • 12.3.3.12. Epigenomics AG
      • 12.3.3.12.1. Company Overview
      • 12.3.3.12.2. Financial Performance
      • 12.3.3.12.3. Product Benchmarking
      • 12.3.3.12.4. Strategic Initiatives
  • 12.3.4. Strategy Mapping
    • 12.3.4.1. Expansion
    • 12.3.4.2. Acquisition
    • 12.3.4.3. Collaborations
    • 12.3.4.4. Disease Type/Drug Class Launch
    • 12.3.4.5. Partnerships
    • 12.3.4.6. Others

관련자료